2024-11-04 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison with S&P 500 (VOO)**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical devices, and consumer goods company. The company has a diversified portfolio of products, including prescription drugs, medical devices, and consumer healthcare products.

**Cumulative Return:**

* **JNJ:** 33.48%
* **S&P 500 (VOO):** 131.78%

**Performance Gap:**

* **Max:** 14.66%
* **Min:** -105.8%
* **Current:** -98.3%
* **Relative Gap:** 6.23% (This means JNJ's performance is currently at the 6.23% percentile of its historical performance range relative to the S&P 500.)

**Alpha & Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|---|---|---|---|---|
| 2015 | -1.1% | 10.1% | -1.5% | 0.0 |
| 2016 | 11.1% | 9.3% | 1.6% | 1.2 |
| 2017 | 21.2% | 5.3% | 1.8% | 1.1 |
| 2018 | -12.0% | 17.5% | -1.4% | 1.1 |
| 2019 | 13.6% | 10.6% | -17.5% | 0.4 |
| 2020 | 8.0% | 27.5% | -12.3% | 0.4 |
| 2021 | 9.0% | 12.1% | -30.2% | 0.2 |
| 2022 | 1.6% | 12.1% | 47.2% | -0.0 |
| 2023 | -19.2% | 16.6% | -53.8% | -0.6 |
| 2024 | 1.2% | 10.9% | -32.3% | 0.0 |

**Analysis:**

* JNJ has underperformed the S&P 500 significantly in recent years.
* The Alpha and Beta analysis indicates that JNJ has been generally less volatile than the market (Beta < 1) but has not delivered significant outperformance (Alpha often negative).

**2. Recent Price Movement:**

* **Last Close:** 160.13
* **5-day Moving Average:** 160.46
* **20-day Moving Average:** 162.02
* **60-day Moving Average:** 162.72

**Analysis:**

* The stock is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a short-term downtrend.

**3. Technical Indicators:**

* **RSI:** 45.82 (Neutral)
* **PPO:** -0.23 (Sell Signal)
* **Delta_Previous_Relative_Divergence:** 0.89 (+) (Short-term upward momentum)
* **Expected Return:** 0.0% (Long-term expected return relative to the S&P 500)

**Analysis:**

* The RSI indicates a neutral sentiment, while the PPO suggests a sell signal. 
* The positive delta in relative divergence points to a short-term upward momentum, suggesting a possible bounce back.
* However, the expected return of 0% indicates that JNJ is not expected to outperform the S&P 500 over the long term.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2024-07-25 | 1.95 | 22.45 B$ |
| 2024-05-01 | 1.35 | 21.38 B$ |
| 2024-02-16 | 1.68 | 21.39 B$ |
| 2023-10-27 | 10.32 | 21.35 B$ |

**Analysis:**

* The company's most recent earnings report on 2024-10-23 showed EPS of 1.12 and revenue of $22.47B, missing analysts' estimates.
* This indicates that the company may be facing some challenges in the current market environment.
* However, the overall revenue trend remains stable and the company continues to maintain its market share. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $22.47B | 69.01% |
| 2024-06-30 | $22.45B | 69.40% |
| 2024-03-31 | $21.38B | 69.55% |
| 2023-12-31 | $21.39B | 68.23% |
| 2023-09-30 | $21.35B | 69.06% |

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $70.16B | 3.84% |
| 2024-06-30 | $71.54B | 6.55% |
| 2024-03-31 | $70.02B | 4.65% |
| 2023-12-31 | $68.77B | 5.89% |
| 2023-09-30 | $71.23B | 36.54% |

**Analysis:**

* JNJ maintains a strong profit margin and a solid track record of profitability.
* The recent decline in ROE suggests that the company may be facing some efficiency challenges, which could be a concern for investors.
* However, the company's large equity base and strong financial position provide a cushion against potential risks.

**6. News & Recent Issues:**

**Recent Earnings News:**

* No significant recent earnings news was found for JNJ within the last 2 days.

**Recent Market Outlook:**

* Recent analyst reports highlight JNJ's solid dividend payout and its resilience during economic downturns.
* The company's focus on healthcare innovation and its diversified portfolio are seen as strengths.
* However, some analysts express concerns about JNJ's exposure to litigation risks and the potential for future regulatory challenges.

**Analyst Opinions & Performance Highlights:**

* **FINBOLD:**  JNJ is rated as a "Strong Buy" with a 1-year target price of $180.
* **Other sources:** The consensus among analysts is that JNJ is a solid long-term investment, but near-term performance may be affected by macroeconomic factors.

**7. Overall Analysis:**

* JNJ has underperformed the S&P 500 in recent years, but remains a financially sound and profitable company.
* The stock is currently in a short-term downtrend, but there is potential for a rebound based on technical indicators.
* The expected return of 0% suggests that JNJ is not expected to outperform the market over the long term.
* JNJ is a dividend-paying company with a solid track record of returning value to shareholders.
* Investors should consider the company's long-term outlook, its exposure to litigation risks, and potential regulatory challenges before making an investment decision.

**8. Recommendation:**

JNJ could be considered a good long-term holding for investors seeking a reliable and dividend-paying company. However, the current underperformance and potential for continued volatility should be factored into investment decisions. The stock may be more attractive to investors who are looking for a stable, long-term investment with a focus on dividends and capital appreciation. 
